The estimated Net Worth of David J Mauro is at least $249 Mille dollars as of 5 October 2021. Dr Mauro owns over 15,000 units of Codiak BioSciences stock worth over $855 and over the last 10 years he sold CDAK stock worth over $247,827.
Dr has made over 11 trades of the Codiak BioSciences stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of CDAK stock worth $28,350 on 5 October 2021.
The largest trade he's ever made was exercising 25,000 units of Codiak BioSciences stock on 27 April 2021 worth over $47,250. On average, Dr trades about 5,925 units every 68 days since 2014. As of 5 October 2021 he still owns at least 15,000 units of Codiak BioSciences stock.
You can see the complete history of Dr Mauro stock trades at the bottom of the page.
Dr. David J. Mauro M.D., Ph.D. is the Chief Medical Officer at Codiak BioSciences.
Dr D is 56, he's been the Chief Medical Officer of Codiak BioSciences since . There are 3 older and 6 younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences, Inc. is Richard Brudnick, 64, who is the Chief Bus. Officer & Head of Corp. Strategy.
David's mailing address filed with the SEC is C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE, MA, 02140.
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch... e Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Codiak BioSciences executives and other stock owners filed with the SEC include: